Shares of Verona Pharma plc ( NASDAQ:VRNA – Get Rating ) have been assigned a consensus recommendation of 'Buy' from the six ratings firms that are presently covering the firm, MarketBeat Ratings reports. Six investment analysts have rated the stock with a buy rating. The average twelve-month target price among brokerages that have covered the stock in the last year is $28.50. VRNA has been the subject of a number of research analyst reports. HC Wainwright raised their target price on Verona Pharma from $30.

https://www.dailypolitical.com/2023/03/09/verona-pharma-plc-nasdaqvrna-receives-consensus-rating-of-buy-from-brokerages.html

#dailypolitical